183 related articles for article (PubMed ID: 12064356)
1. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats.
Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T
Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356
[TBL] [Abstract][Full Text] [Related]
2. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.
Baslow MH
J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786
[TBL] [Abstract][Full Text] [Related]
3. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
4. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
5. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
Baslow MH; Resnik TR
J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
[TBL] [Abstract][Full Text] [Related]
6. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions.
Baslow MH; Guilfoyle DN
Biochimie; 2013 Apr; 95(4):946-56. PubMed ID: 23151389
[TBL] [Abstract][Full Text] [Related]
7. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
8. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model.
Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D
Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859
[TBL] [Abstract][Full Text] [Related]
9. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
10. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation.
Baslow MH
J Mol Neurosci; 2003; 21(3):185-90. PubMed ID: 14645985
[TBL] [Abstract][Full Text] [Related]
11. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
12. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
13. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes.
Baslow MH; Suckow RF; Sapirstein V; Hungund BL
J Mol Neurosci; 1999; 13(1-2):47-53. PubMed ID: 10691291
[TBL] [Abstract][Full Text] [Related]
14. Effects of ethanol and of alcohol dehydrogenase inhibitors on the reduction of N-acetylaspartate levels of brain in mice in vivo: a search for substances that may have therapeutic value in the treatment of Canavan disease.
Baslow MH; Suckow RF; Hungund BL
J Inherit Metab Dis; 2000 Nov; 23(7):684-92. PubMed ID: 11117430
[TBL] [Abstract][Full Text] [Related]
15. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
[TBL] [Abstract][Full Text] [Related]
16. Lithium citrate for Canavan disease.
Janson CG; Assadi M; Francis J; Bilaniuk L; Shera D; Leone P
Pediatr Neurol; 2005 Oct; 33(4):235-43. PubMed ID: 16194720
[TBL] [Abstract][Full Text] [Related]
17. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
[TBL] [Abstract][Full Text] [Related]
18. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
[TBL] [Abstract][Full Text] [Related]
19. Canavan disease: a monogenic trait with complex genomic interaction.
Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
[TBL] [Abstract][Full Text] [Related]
20. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]